Review of the contribution of radiolabelled tracers for tumour cell status imaging

被引:4
作者
Nathalie, Perek [1 ]
Nathalie, Le Jeune [1 ]
Delphine, Denoyer [1 ]
Nathalie, Prevot [1 ]
Dubois, Francis [1 ]
机构
[1] Fac Med, Lab Biophys & Radiopharmaceut, Cell Death & Neoplasia Grp, F-42023 St Etienne 02, France
关键词
PET; SPECT; tumour metabolism; radiotracer; apoptosis; MDR; proliferation;
D O I
10.2174/157340506776930647
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Cancer develops as a result of an imbalance between cell proliferation and programmed cell death or apoptosis. Tumour cells are characterised by prolonged survival and uncontrolled proliferation. Tumour cells also acquire new functions, such as the capacity to migrate and colonise other organs by forming metastases. Cancer chemotherapy mainly acts by inducing apoptosis. However, resistance of human malignancies to multiple chemotherapeutic agents remains a major obstacle to the efficacy of treatment. Radiolabelled tracers used in Single Photon Emission Computed Tomography (SPECT) and more recently in Positron Emission Tomography (PET) screening in nuclear medicine have been developed to directly visualise in vivo biochemical and physiological parameters of tumour cells. These functional and molecular techniques have become an excellent research tool to study in vivo tumour biology. For instance, proliferation, apoptosis and multidrug resistance tracers have been complexed and studied on in vitro cellular models and several in vivo applications have been developed in the management of cancer patients. In this review, we focus on the radiotracers elaborated in the field of proliferation, apoptosis and MDR. We summarise the most recent studies in SPECT and PET imaging and their possible applications in oncology.
引用
收藏
页码:193 / 203
页数:11
相关论文
共 116 条
[1]   Choline phospholipid metabolism: A target in cancer cells? [J].
Ackerstaff, E ;
Glunde, K ;
Bhujwalla, ZM .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2003, 90 (03) :525-533
[2]   Biochemical, cellular, and pharmacological aspects of the multidrug transporter [J].
Ambudkar, SV ;
Dey, S ;
Hrycyna, CA ;
Ramachandra, M ;
Pastan, I ;
Gottesman, MM .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 :361-398
[3]   Structure and function of choline kinase isoforms in mammalian cells [J].
Aoyama, C ;
Liao, HN ;
Ishidate, K .
PROGRESS IN LIPID RESEARCH, 2004, 43 (03) :266-281
[4]  
Atasever T, 1997, NUKLEARMED, V36, P223
[5]  
Barbarics E, 1998, CANCER RES, V58, P276
[6]  
Barthel H, 2003, CANCER RES, V63, P3791
[7]  
BARTHEL H, 2004, EUR J NUCL MED MOL I, V4, P4
[8]   [18F]FLT-PET in oncology:: current status and opportunities [J].
Been, LB ;
Suurmeijer, AJH ;
Cobben, DCP ;
Jager, PL ;
Hoekstra, HJ ;
Elsinga, PH .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (12) :1659-1672
[9]   Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC) [J].
Bellon, JR ;
Livingston, RB ;
Eubank, WB ;
Gralow, JR ;
Ellis, GK ;
Dunnwald, LK ;
Mankoff, DA .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (04) :407-410
[10]  
Blankenberg F, 1999, Q J NUCL MED, V43, P170